Blood Donation: Separating Myth From Fact

After natural disasters and other tragic events, many people try to help by rushing to the nearest blood donation center. While there’s no denying that many of the victims of tragedies require blood transfusions,...

Online Exclusives

IV Bag Shortage Making Flu Season Worse

Supplies of intravenous (IV) saline and nutrient solutions were already tight before hurricanes hit Puerto Rico and cut power to manufacturing plants. Now, as...

Eltrombopag Receives Breakthrough Designation

The U.S. Food and Drug Administration granted breakthrough therapy designation to eltrombopag for firstline treatment of severe aplastic anemia (AA). The designation is based...

News

From the Blood Journals

WIB_icon

Does Red Cell Exchange Transfusion Lower Stroke Risk in Pediatric Patients...

Although chronic transfusion therapy (CTT) reduces the risk of primary or recurrent stroke in pediatric patients with sickle cell anemia (SCA), it introduces long-term...
WIB_icon

Combining Romidepsin and Pralatrexate in Relapsed/Refractory T-Cell Lymphoma: Are Two Drugs...

In a phase I trial of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL), combining romidepsin and pralatrexate – two agents approved by the U.S....

Multimedia

video

Luc-Matthieu Fornecker, MD, PhD: Risks and Benefits of BV + AVD...

In the multicenter BREACH trial, adding brentuximab vedotin to AVD chemotherapy in patients with unfavorable, early-stage Hodgkin lymphoma led to higher rates of PET...
video

Prithviraj Bose, MD: Optimizing Ruxolitinib With Sotatercept for Myelofibrosis

Dr. Bose discusses updated results from a phase II trial of sotatercept alone and with ruxolitinib, the only FDA-approved therapy for myelofibrosis, which also...
video

Jeanette K. Doorduijn, MD, PhD, and Samar Issa, MD: Does Rituximab...

Results from a randomized phase III trial examining rituximab in patients with central nervous lymphoma show that treatment with rituximab does not improve response...
video

James N. Kochenderfer, MD: Advancing CAR T-Cell Therapy for Myeloma

Dr. Kochenderfer reports "very exciting" results from bb121, a new BCMA-targeting CAR T-cell therapy for treating patients with heavily pretreated myeloma, trending towards less...

On Location

“Intra-Bone” Gene Therapy Reduced Transfusion Need in Patients With Beta-Thalassemia

Gene therapy could represent an alternative to hematopoietic stem cell transplantation (HCT) – the only...

Two Versus Three Cycles of Consolidation Therapy for Patients With AML

Patients with core-binding factor acute myeloid leukemia (CBF-AML) who received only two cycles of consolidation...

Catching Up With First-Time Attendees

In December 2017, we introduced you to two first-time ASH annual meeting attendees: Kelly Schoenbeck...

Could Adding Sotatercept to Ruxolitinib Improve MPN-Associated MF and Anemia?

The JAK1 inhibitor ruxolitinib is the only therapy approved by the U.S. Food and Drug...

Will Replacing Bleomycin With Brentuximab Vedotin Revolutionize Frontline Hodgkin Lymphoma Treatment?

For patients with advanced-stage Hodgkin lymphoma (HL), eliminating bleomycin (and its associated risks of pulmonary...

Newly Approved Drugs in ALL and NHL: How to Use Them in Practice

In 2017, the U.S. Food and Drug Administration (FDA) approved several therapies for the treatment...

Latest Headlines

Advertisement

ASH Directions

ASH Announces 2018 Scholar Award Recipients, New Ambassador Program, and more

Introducing the ASH Ambassador Program The ASH Ambassador Program supports recruitment and retention of trainees to hematology and to the Society, particularly underrepresented minorities, through...

Harnessing Big Data’s Power, Updates to the Research Agenda, and more

Harnessing Big Data’s Power and Potential In keeping with the mission of helping hematologists conquer blood diseases worldwide, the American Society of Hematology (ASH) has...

Sign up for our
eNewsletter!

California Institute for Regenerative Medicine Awards Grant, University of California San Diego School of...

Barbara Savoldo Receives Grant From LLS for CAR T-Cell Research Barbara Savoldo, MD, PhD, assistant director of the Immunotherapy Program at the University of North...

National Academy of Medicine Announces New Hematology/Oncology Members, Winship Cancer Institute Earns NCI Designation,...

Emory University’s Winship Cancer Institute Earns NCI Designation Winship Cancer Institute of Emory University in Atlanta, Georgia, was granted comprehensive cancer center designation by the...

Cancer Immunologist Receives New Innovator Award, Launch of Kids First Data Resource Center, and...

LSU Receives $10 Million Grant to Study Virus-Induced Cancers Louisiana State University (LSU) Health New Orleans received a five-year, $10 million grant from the National...

Blood Donation: Separating Myth From Fact

After natural disasters and other tragic events, many people try to help by rushing to the nearest blood donation center. While there’s no denying...

Gun Violence: A Public Health Crisis

Does the oath to “do no harm” conflict with the right to bear arms? Issues related to gun violence and regulation are among the most...

What are Biosimilars?

Defining the new category and exploring physicians’ attitudes about biosimilars in the marketplace A growing number of biosimilars are making their way through the drug...